MC
KERX

Moors & Cabot’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Moors & Cabot’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$72K – 558
2017
Q2 		$72K Hold
10,000
– – 0.01% 495
2017
Q1 		$61K Buy
+10,000
New +$54.8K 0.01% 496

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Moors & Cabot's KERX Position: Q3 2017 in Review

Moors & Cabot sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2017, closing a stake of 10,000 shares — an estimated $72K sold.

Moors & Cabot first reported a position in KERX in Q1 2017 and held it in 2 quarters. The position peaked at $72K in Q2 2017. 132 funds tracked by Wall St. Rank hold KERX as of Q3 2017.

  • Moors & Cabot reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Moors & Cabot sold 10,000 Keryx Biopharmaceuticals Inc shares in Q3 2017, an estimated $72K.
  • Moors & Cabot first reported a position in Keryx Biopharmaceuticals Inc in Q1 2017 and held it in 2 quarters.
  • Moors & Cabot's Keryx Biopharmaceuticals Inc position peaked at $72K in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2017.

Based on Moors & Cabot's 13F filing for Q3 2017, filed 16 Nov 2017.